o nco p anel and profiling services therapeutic strategies ... … · o nco p anel cell-based...

PHARMA PHARMA PHARMA PHARMA PHARMA DISCOVERY DISCOVERY DISCOVERY DISCOVERY EXPERTISE EXPERTISE EXPERTISE EXPERTISE PHARMA PHARMA PHARMA PHARMA PHARMA DISCOVERY DISCOVERY DISCOVERY DISCOVERY




OncoPanel™ CELL-BASED SCREENING AND PROFILING SERVICESTherapeutic Strategies for Oncology with Cellular and Genomic Profiling

Eurofins Discovery.Deep resources for success.

1

A ROBUST DRUG RESPONSE PLATFORM WITH CUSTOM OPTIONS TO DRIVE ONCOLOGY THERAPEUTIC DISCOVERY AND DEVELOPMENT, OFFERED EXCLUSIVELY BY Eurofins Discovery.

Over 300 2D and 100 3D spheroid human cancer cell line models drive design of epigenetic, kinase, gene family, and target-focused expression panels, making thorough candidate assessment possible.

OncoPanel HUMAN-CENTERED DATA POWERS A MORE TARGETED AND EFFICIENT CLINICAL TRIAL DESIGN.

Use OncoPanel profiling to improve patient stratification prior to clinical trial launch. Early identification of genomic biomarkers of response provides insights on genomic features that may predispose patients to therapeutic responses or identify potential resistance mechanisms.

OncoPanel™ CELL-BASED SCREENING AND PROFILING SERVICES

Flexibility and expertise to suit your oncology program needs

300+ Cancer Cell Lines

80+ Clients

60+ Reference Benchmark Compounds

19 Distinct Tissue Lineages

274,000 Genetic Aberrations

100+ Spheroid Models

10+ Years Experience

2

COMPREHENSIVE ASSESSMENT WITH DEPTH AND BREADTH INFORMS ON TEST AGENT POTENCY, TISSUE LINEAGE SENSITIVITY, GENOMIC ALTERATIONS, AND RESISTANCE STRATIFICATION.

Figure 3. Identification of mutations associated with sensitivity or resistance to Nutlin-3 (an MDM2 inhibitor) treatment of OncoPanel human tumor cell lines.

0.50.4

0.30.20.1

-0.10

-0.2-0.3-0.4-0.5

-0.6

-0.7

-0.8-0.9

-15 -10 -5 0 5 10 15 20 25

Odds Ratio

Effe

ct

Resistance

Sensitivity

• Reveal statistically significant genomic features – including amplifications, mutations, deletions, and differential gene expression – associated with drug sensitivity or resistance

• Confirm in vitro the results of test agent profiling or screening outcomes

• Rank test agents for further lead optimization

Figure 2. Impact of the BRAF inhibitor vemurafenib on cell proliferation across 300+ human cancer cell lines representing 18 different tissue types/subtypes—as revealed by OncoPanel screening.

Skin

(Mel

anom

a)C

olon

Soft

Tiss

ues

Endo

crin

eSt

omac

hLi

ver

Cen

tral N

ervo

usSy

stem

Hem

atop

oiet

icPa

ncre

asKi

dney

Blad

der

Fem

ale

GU

Brea

st

Lung

Plac

enta

Pros

tate

Eye

Hea

d an

d N

eck

1.5

1.0

0.5

0.0

-0.5

-1.5

-1.0

Log 10

IC50

• Differentiate tissue and tumor lineage types most sensitive to drug or combination approaches

• Identify therapeutic oncological indications for maximal potential clinical efficacy

• Rank tissue types based on cell viability, proliferation, apoptosis induction, and cell cycle arrest

Figure 1. Example drug response curves with half maximum effective concentration (EC50), half maximal inhibitory concentration (IC50), and half maximal inhibition of cell growth (GI50).

Cel

l Cou

nt, %

Con

trol

Compound, µM

100

75

50

GI50

T0IC50EC50

25

0

Curve Bottom

0% Control

3

MAXIMUM FLEXIBILITY WITH STANDARD AND CUSTOM OPTIONS

Profile test agents, or test agent combinations, in the comprehensive, 300+ cell line panel or in smaller lineage-type or gene-specific subpanels of interest. All cell lines are licensed from ATCC, Memorial Sloan-Kettering, or other commercial vendors ensuring freedom to operate, are kept at low passage, and are consistently monitored for growth characteristics to ensure robust, reproducible responses.

For a complete and up-to-date list of available cell lines and genetic targets, please contact [email protected]

BRING THE POWER OF GENOMIC ANALYSIS TO YOUR DRUG DISCOVERY AND DEVELOPMENT EFFORTS

Figure 4. Pie chart of 19 different tissue or tumor lineage types represented in OncoPanel.

EXPANDED INSIGHTS WITH 3D SPHEROID MODELS

Spheroids offer certain advantages over 2D models, including representation of solid tumor hypoxia, pH, and nutrient gradients. Over one hundred cancer cell lines are available as 3D models in a customizable assay format, with up to seven days drug exposure options.

Figure 5. Spheroid models of four different tumor cell lines imaged at 10X magnification under brightfield illumination prior to test agent addition, as part of routine QC processes.

Lymphoma

Colon

Lung

Central Nervous System

Skin

Leukemia

Female GU

Soft Tissue & Bone

Breast

Pancreas

Bladder

Head and Neck

KidneyEndocrine

Liver

ProstateStomach

MyelomaOther

Target Class Gene ExamplesKinases BRAF, FLT3, PIK3CA

Growth factor receptors EGFR, IGF1R, MET

G-protein coupled receptors CNR1/CNR2, DRD2, SMO

Ion channels ABCC9, KCNH2, KCNK2

Transcription factors ESR1, MYC, STAT3

Enzymes KRAS, PARP1, TNKS

Epigenetic targets BRD4, EZH2, HDAC1

25,000+ genes available for creation of custom cell panels to inform on test agent impact.

A-673 Ewing’s sarcoma

G-361 Melanoma

LS411N Colorectal carcinoma

PC3Prostate adenocarcinoma

mailto:phenotypicsupport%40eurofins.com?subject=

4

IDENTIFY MARKERS PREDICTIVE OF TREATMENT RESPONSE

The OncoPanel™ platform uniquely offers extensive genomic analysis of human cancer cell line drug responses. Detailed genomic information allows for the statistical correlation of test responses (both sensitivity and resistance) with specific genomic features, such as mutations or copy number variations, to inform on patient stratification.

IDENTIFY PATHWAYS OR PROCESSES IMPLICATED IN DRUG RESPONSES

For defined pathway mechanisms, differential gene expression analysis can provide insights into individual biomarkers for further evaluation and potential asset repositioning.

Figure 6. A database of genomic features evaluated for correlation to PD0325901 responsiveness, as measured by cell count IC50. Use of orthogonal Student’s t-test (x axis) and Fisher’s exact test (y axis) address mathematical bias, allowing identification of biologically relevant features significant by both. Genomic features satisfying both significance thresholds, and with q-values (FDR) <0.1, are colored dark green and annotated.

Figure 7. A. Volcano plot showing differentially expressed genes associated with resistance or sensitivity to Nutlin-3 inhibition of MDM2 activity. MDM2 is an E3 family ubiquitin ligase. B. Pathway analysis of differentially expressed genes identified in response to Nutlin-3 treatment.

A B

-Log

10 P

-Val

ue

Fold Change

Resistant Sensitive

1% FDR

-20 -15 -10 -5 0 5 10 15 20

20

18

16

14

12

10

8

6

4

2

0

signal transduction by p53 class mediator

intrinsic apoptoticsignaling pathway by p53 class mediator

cellular response to stress

intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator

mitotic DNA damage checkpoint

intrinsic apoptotic signaling pathway in response to DNA damage

DNA damage checkpoint

DNA integritycheckpoint

mitochondrion organization

response to UV

mitotic DNA integrity checkpoint

response to stress

p53 signaling pathway

cellular response to DNA damage stimulus

mitotic cell cyclecheckpoint

5

4.5

4

3.5

3

2.5

2

1.5

1

0.5

0

43.532.521.510.5 4.50

-Log

10 P

-Val

ue, F

ishe

r’s e

xact

test

-Log10 P-Value, Student’s t-test

Amplified

Deleted

Mutated

Mutated or Amplified

Mutated or Deleted

Size by:

Average (Mutation Count)

≥ 159.00

≤ 3.00

5

Figure 8. Hierarchical clustering of vemurafenib EC50 values across all cell lines to the equivalent values for agents in the OncoPanel reference database reveals that the BRAF inhibitor vemurafenib clusters most closely with another BRAF inhibitor, PLX4720. Top row = target protein name, bottom row = test agent name.

Figure 9. Bliss excess based on combination testing for multiple cell lines treated with the same combination of agents. This excess is converted into the Bliss sum, which shows whether the combination is antagonistic (negative) or synergistic (positive) for all concentration combinations, per individual cell line.

BENCHMARK TEST AGENTS TO INFORM ON CLINICAL POTENTIAL

• Gain understanding of biological impact and clinical potential, from small molecules to biologics

• Perform competitive benchmarking to over 60 standard-of-care agents and reference tools

ADDRESS EFFICACY AND RESISTANCE CHALLENGES WITH DRUG COMBINATION STRATEGIES

• OncoPanel™ offers 9x9 combination matrix testing across subpanels, individual OncoPanel cell lines, or custom cell lines

• Analysis includes calculation of combination indices, individual test agent dose responses, and determination of excess over Bliss independence

ENHANCE YOUR PRECLINICAL KNOWLEDGE BASE: INSIGHTS ON EFFICACY, MECHANISM OF ACTION, AND BIOMARKER IMPACT

Bliss Excess

Test

Age

nt C

once

ntra

tion

(μM

)

1.56E-004

3.13E-004

6.25E-004

1.25E-003

5.00E-003

2.50E-003

1.00E-002

2.00E-002

4.00E-002

8.00E-002

SW94

8SK

-N-F

lH

TR

amos

(RA

1)D

BTR

G-0

5MG

CAL

-62

U26

6B1

Hs7

66T

HT-

1080

Y79

CAM

A-1

SW83

7SW

954

RPM

I-795

1C

haG

oK1

HT-

3D

aoy

OC

UG

-1M

ALM

E3M

HEL

-92-

1-7

HEL

-9U

SOS

SNU

-423

EM-2

YAPC

SW57

9N

CI-H

441

C32

TGC

HP-

212

SCC

4AC

HN

WiD

rA3

75AR

H-7

7A1

72AG

SN

CI-H

661

CaO

V3Sa

OS2

T98G

SK-N

-FI

SNU

-1D

audi

SK-B

R-3

CM

L-T1

SJR

H30

Ram

os (R

A 1)

SW-1

3ST

486

Blis

s Su

m

3.5

3

2.5

2

1.5

1

0.5

0

-0.5

-1

-1.5

-2

6

CONTACT US

Work with our technical and scientific experts to find out how OncoPanel™ Screening and Profiling Services can accelerate your drug discovery and development efforts. Our phenotypic experts are ready to assist in designing an approach to meet your program needs and quickly advance your projects. OncoPanel may be customized, and used for therapeutic areas outside oncology.

Get in touch at [email protected]

Eurofins Discovery Phenotypic Services—easing your path on the journey from concept to clinic.Contact us at: [email protected] or visit us on the web at: eurofinsdiscoveryservices.com/phenotypic

PARTIAL OncoPanel CATALOG INFORMATION

Catalog Item DescriptionPSOP0001 OncoPanel, Full 3D Spheroid Panel, with 2D Control, Cell Viability OncoPanel 3D with 2D Control

PSOP0002 OncoPanel, Full 3D Spheroid Panel, without 2D Control, Cell Viability OncoPanel 3D no 2D Control

PSOP0010 OncoPanel, Full Panel: High Content Imaging Cell Proliferation Assay, 10-day long-term 10-day singleplex

PSOP0011 OncoPanel, Full Panel: High Content Imaging Cell Proliferation Assay, 3-day 3-day singleplex

PSOP0012 OncoPanel, Full Panel: High Content Imaging Cell Proliferation Assay, 5-day 5-day singleplex

PSOP0013 OncoPanel, Full Panel: Multi-Parameter High Content Profiling Assay, 10-day long-term 10-day multiplex

PSOP0014 OncoPanel, Full Panel: Multi-Parameter High Content Profiling Assay, 3-day 3-day multiplex

PSOP0015 OncoPanel, Full Panel: Multi-Parameter High Content Profiling Assay, 5-day 5-day multiplex

PSOP0079 Cell Viability in Full OncoPanel: Luminescence Assay, 10-day long-term 10-day cell viability

PSOP0080 Cell Viability in Full OncoPanel: Luminescence Assay, 5-day 5-day cell viability

PSOP0081 Cell Viability in Full OncoPanel: Luminescence Assay, 3-day 3-day cell viability

PSOP0082 OncoPanel Genomics Analysis, Add-On or Custom OncoPanel Genomics Analysis

mailto:phenotypicsupport%40eurofins.com?subject=OncoPanel%20Inquiry

mailto:[email protected]

https://www.eurofinsdiscoveryservices.com/cms/cms-content/services/phenotypic-assays/

o nco p anel and profiling services therapeutic strategies ... … · o nco p anel cell-based...

Documents